CN1210262C - 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 - Google Patents

1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 Download PDF

Info

Publication number
CN1210262C
CN1210262C CNB011171715A CN01117171A CN1210262C CN 1210262 C CN1210262 C CN 1210262C CN B011171715 A CNB011171715 A CN B011171715A CN 01117171 A CN01117171 A CN 01117171A CN 1210262 C CN1210262 C CN 1210262C
Authority
CN
China
Prior art keywords
hydroxyphenyl
tartrate
hydroxy
phenylpiperidin
propanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB011171715A
Other languages
English (en)
Chinese (zh)
Other versions
CN1321638A (zh
Inventor
J·P·雷恩维勒
T·G·小希内
S·W·沃林斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1321638A publication Critical patent/CN1321638A/zh
Application granted granted Critical
Publication of CN1210262C publication Critical patent/CN1210262C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
CNB011171715A 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 Expired - Fee Related CN1210262C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28
US60/200,673 2000-04-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100586743A Division CN1590373A (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法

Publications (2)

Publication Number Publication Date
CN1321638A CN1321638A (zh) 2001-11-14
CN1210262C true CN1210262C (zh) 2005-07-13

Family

ID=22742684

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB011171715A Expired - Fee Related CN1210262C (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法
CNA2004100586743A Pending CN1590373A (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100586743A Pending CN1590373A (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法

Country Status (27)

Country Link
US (1) US6645986B2 (enExample)
EP (2) EP1477479A1 (enExample)
JP (2) JP3615496B2 (enExample)
KR (1) KR100442718B1 (enExample)
CN (2) CN1210262C (enExample)
AR (1) AR028376A1 (enExample)
AT (1) ATE277014T1 (enExample)
AU (1) AU781436B2 (enExample)
BR (1) BR0101630A (enExample)
CA (1) CA2345582C (enExample)
CZ (1) CZ20011471A3 (enExample)
DE (1) DE60105689T2 (enExample)
DK (1) DK1151995T3 (enExample)
ES (1) ES2227071T3 (enExample)
HK (1) HK1040246B (enExample)
HU (1) HUP0101723A3 (enExample)
ID (1) ID30006A (enExample)
IL (1) IL142705A0 (enExample)
IN (1) IN191027B (enExample)
PL (1) PL347298A1 (enExample)
PT (1) PT1151995E (enExample)
RU (1) RU2203888C2 (enExample)
SI (1) SI1151995T1 (enExample)
TR (1) TR200402696T4 (enExample)
TW (1) TW200505858A (enExample)
YU (1) YU27701A (enExample)
ZA (1) ZA200103320B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117556T2 (de) * 2000-06-21 2006-11-02 Bioarray Solutions Ltd. Multianalytische molekularanalyse durch verwendung anwendungsspezifischer zufallspartikelarrays
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN1930304B (zh) * 2003-11-21 2016-01-06 Anp技术公司 不对称支化的聚合物缀合物和微阵列检测
US8563329B2 (en) 2005-05-02 2013-10-22 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
BR9610766A (pt) * 1995-08-11 1999-07-13 Pfizer Triihdrato de metanossulfonato de (1s,2s)-1-(4-hidróxi-fenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanol

Also Published As

Publication number Publication date
KR20010098960A (ko) 2001-11-08
CZ20011471A3 (cs) 2002-02-13
PL347298A1 (en) 2001-11-05
US6645986B2 (en) 2003-11-11
HU0101723D0 (en) 2001-07-30
ZA200103320B (en) 2002-10-24
RU2203888C2 (ru) 2003-05-10
IN191027B (enExample) 2003-09-13
KR100442718B1 (ko) 2004-08-02
AR028376A1 (es) 2003-05-07
DE60105689T2 (de) 2005-11-10
HUP0101723A2 (hu) 2002-02-28
JP3615496B2 (ja) 2005-02-02
AU781436B2 (en) 2005-05-26
ID30006A (id) 2001-11-01
DK1151995T3 (da) 2004-12-13
ES2227071T3 (es) 2005-04-01
DE60105689D1 (de) 2004-10-28
IL142705A0 (en) 2002-03-10
HUP0101723A3 (en) 2003-03-28
SI1151995T1 (en) 2004-12-31
JP2004196823A (ja) 2004-07-15
TR200402696T4 (tr) 2004-11-22
AU3889601A (en) 2001-11-01
HK1040246B (zh) 2005-10-28
ATE277014T1 (de) 2004-10-15
CN1321638A (zh) 2001-11-14
EP1477479A1 (en) 2004-11-17
TW200505858A (en) 2005-02-16
US20020016465A1 (en) 2002-02-07
EP1151995B1 (en) 2004-09-22
CA2345582A1 (en) 2001-10-28
PT1151995E (pt) 2004-11-30
JP2001354651A (ja) 2001-12-25
YU27701A (sh) 2003-04-30
EP1151995A1 (en) 2001-11-07
BR0101630A (pt) 2001-12-04
HK1040246A1 (en) 2002-05-31
CA2345582C (en) 2006-05-30
CN1590373A (zh) 2005-03-09

Similar Documents

Publication Publication Date Title
EP0843661B1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
US5716961A (en) Treatment of tinnitus using neuroprotective agents
CN1048247C (zh) 神经保护的苯并二氢吡喃化合物
CN1210262C (zh) 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法
CN1095719A (zh) 神经保护性3，4-二氢-2(1h)-喹诺酮类化合物
RU2192415C1 (ru) Способ получения мезилат тригидрата 1-(4-гидроксифенил)-2-(4-гидрокси-4-фенилпиперидин-1-ил)-1-пропанола и промежуточные продукты
HK1070644A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
MXPA01004288A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)- 2-(4-hydroxy-4- phenylpiperidin-1-yl)- 1-propanol
HK1073790A (en) (1s, 2s) -1- (4-hydroxyphenyl) -2- (4-hydroxy -4- phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
MXPA01004289A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl) -2-(4-hydroxy-4- phenylpiperidin -1-yl) -1-propanol and intermediates useful therefor

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee